← Leaderboards
Brent L Wood
National Childhood Cancer Foundation
$2,612,469
Attributed
$10,300,704
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,300,704 · 3
By mechanism
R01$8,591,754 · 2
RC2$1,708,950 · 1
Top collaborators
- Michelle L Hermiston8 shared
- Terzah M Horton8 shared
- David T. Teachey8 shared
- Harlan S. Robins5 shared
- David Wu5 shared
- Michael J Borowitz2 shared
- Meenakshi Devidas2 shared
- Julie M Gastier-Foster2 shared
Most similar at National Childhood Cancer Foundation
Same institution · by research overlap
- Julie M Gastier-Foster$11,724,621
- Gregory H Reaman$54,308,094
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsChemotherapyRelapseT-LymphocyteSamplingDesignBaseDiagnosisPediatric Oncology GroupFlow CytometryBone MarrowResponseBiologyHigh RiskPathway InteractionsChildCohortDeep SequencingResidual NeoplasmClinical DataPhase Iii Clinical TrialsBortezomibAcute T Cell LeukemiaInternational
Grant awards (15)
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$737,926
R01 · FY2025 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$721,069
R01 · FY2024 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$851,561
R01 · FY2023 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$575,456
R01 · FY2019 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$594,741
R01 · FY2018 · CA
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu$544,480
R01 · FY2018 · CA
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu$648,389
R01 · FY2017 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$625,779
R01 · FY2017 · CA
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu$648,389
R01 · FY2016 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$626,176
R01 · FY2016 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$709,314
R01 · FY2015 · CA
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu$648,389
R01 · FY2015 · CA
Deep sequencing for minimal residual disease detection in Acute Lymphoblastic Leu$660,085
R01 · FY2014 · CA
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$876,194
RC2 · FY2010 · CA
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$832,756
RC2 · FY2009 · CA